Search Results - "Lazanas, M."

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART by VAN LETH, F, ANDREWS, S, GRINSZTEJN, B, WILKINS, E, LAZANAS, M. K, LANGE, J. M. A, MONTANER, J

“…A substantial number of patients start their first-line antiretroviral therapy at an advanced stage of an HIV-1 infection. Potential differences between…”
Get full text

HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report by Paraskevis, D, Nikolopoulos, G, Tsiara, C, Paraskeva, D, Antoniadou, A, Lazanas, M, Gargalianos, P, Psychogiou, M, Malliori, M, Kremastinou, J, Hatzakis, A

“…A significant increase (more than 10-fold) in the number of newly diagnosed HIV-1 infections among injecting drug users (IDUs) was observed in Greece during…”
Get full text

Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003–2015: Transmitted drug resistance is due to onward transmissions by Paraskevis, D., Kostaki, E., Magiorkinis, G., Gargalianos, P., Xylomenos, G., Magiorkinis, E., Lazanas, M., Chini, M., Nikolopoulos, G., Skoutelis, A., Papastamopoulos, V., Antoniadou, A., Papadopoulos, A., Psichogiou, M., Daikos, G.L., Oikonomopoulou, M., Zavitsanou, A., Chrysos, G., Paparizos, V., Kourkounti, S., Sambatakou, H., Sipsas, N.V., Lada, M., Panagopoulos, P., Maltezos, E., Drimis, S., Hatzakis, A.

“…The prevalence of HIV-1 drug resistance among treatment-naïve patients ranges between 8.3% and 15% in Europe and North America. Previous studies showed that…”
Get full text

Estimation of the Direct Cost of HIV-Infected Patients in Greece on an Annual Basis by Boubouchairopoulou, Nadia, Athanasakis, Kostas, Chini, Maria, Mangafas, Nikos, Lazanas, M.K., Kyriopoulos, John E.

“…HIV infection is currently regarded as a global chronic disease. The purpose of this study was to assess the direct cost of illness per patient per year in…”
Get full text

Bacterial flora in residents of long-term care facilities: a point prevalence study by Kanellakopoulou, K, Grammelis, V, Baziaka, F, Volonaki, A, Gika, M, Lazanas, M, Giamarellou, H

Get full text

Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen by Chini, M, Tsoupras, A B, Mangafas, N, Tsogas, N, Papakonstantinou, V D, Fragopoulou, E, Antonopoulou, S, Gargalianos, P, Demopoulos, C A, Lazanas, M C

“…Human Immunodeficiency Virus (HIV)-infected patients are at increased risk for cardiovascular diseases partly due to chronic inflammation. Some antiretroviral…”
Get more information

In Vivo Effects of a Ginkgo Biloba Extract on Platelet Activating Factor Metabolism in Two Asymptomatic Hiv-Infected Patients by Tsoupras, A.B., Chini, M., Tsogas, N., Mangafas, N., Demopoulos, C.A., Lazanas, M.C.

“…Ginkgo biloba products seem to protect from several pathological conditions, including HIV manifestations, where Platelet Activating Factor (PAF) is…”
Get full text

Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece by Paraskevis, D., Magiorkinis, E., Katsoulidou, A., Hatzitheodorou, E., Antoniadou, A., Papadopoulos, A., Poulakou, G., Paparizos, V., Botsi, C., Stavrianeas, N., Lelekis, M., Chini, M., Gargalianos, P., Magafas, N., Lazanas, M., Chryssos, G., Petrikkos, G., Panos, G., Kordossis, T., Theodoridou, M., Sypsa, V., Hatzakis, A.

“…The prevalence of HIV-1 drug resistance mutations in naïve patients has been previously shown to differ greatly with the geographic origin. The purpose of this…”
Get full text

Prevalence study of hospital-acquired infections in 14 Greek hospitals: planning from the local to the national surveillance level by Gikas, A., Pediaditis, J., Papadakis, J.A., Starakis, J., Levidiotou, S., Nikolaides, P., Kioumis, G., Maltezos, E., Lazanas, M., Anevlavis, E., Roubelaki, M., Tselentis, Y.

“…A prevalence study of hospital-acquired infections (HAI) was carried out in 14 of 112 Greek hospitals (15.7%), scattered throughout Greece. Five of seven Greek…”
Get full text

HPR165 Defining a Global Disease Budget for HIV in Greece by Theodoratou, D, Paraskevis, D, Lazanas, M, Souliotis, K

Get full text

Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors by Tsekes, G, Chrysos, G, Douskas, G, Paraskeva, D, Mangafas, N, Giannakopoulos, D, Papanikolaou, M, Georgiou, E, Lazanas, MC

“…Objectives In the era of highly active antiretroviral treatment (HAART), there are insufficient data regarding lipodystrophy syndromes in HIV‐1‐infected…”
Get full text

HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries by van de Vijver, D A M C, Wensing, A M J, Åsjö, B, Bruckova, M, Jorgensen, L B, Camacho, R, Horban, A, Linka, M, Lazanas, M, Loveday, C, MacRae, E, Nielsen, C, Paraskevis, D, Poljak, M, Puchhammer-Stöckl, E, Ruiz, L, Schmit, J-C, Stanczak, G, Stanojevic, M, Vandamme, A-M, Vercauteren, J, Zazzi, M, Bacheler, L, Lecocq, P, Villacian, J, Boucher, C A B

“…Information about patterns of HIV-1 drug resistance among treatment-exposed patients is crucial for the development of novel effective drugs. Currently no…”
Get full text

P1919 Factors correlated with adherence to HAART: a multicentre study from an HIV–infected Greek population by Pitsounis, N, Peristeraki, S, Tsogas, N, Mangafas, N, Chini, M, Lioni, A, Skoutelis, A, Nikolaides, P, Gargalianos, P, Panos, G, Kordosis, T, Paparizos, V, Gikas, A, Moschou, M, Chrysos, G, Koratzanis, G, Lazanas, M

Get full text

Molecular characterization of a complex, recombinant human immunodeficiency virus type 1 (HIV-1) isolate (A/G/J/K/?): evidence to support the existence of a novel HIV-1 subtype by Paraskevis, D, Magiorkinis, E, Magiorkinis, G, Anastassopoulou, C, Lazanas, M, Chrysos, G, Vandamme, A. M, Hatzakis, A

“…National Retrovirus Reference Center, Department of Hygiene and Epidemiology, Athens University Medical School, 75 Mikras Asias Street, GR-115 27 Athens…”
Get full text

Mutations associated with genotypic resistance to antiretroviral therapy in treatment naïve HIV-1 infected patients in Greece by Magiorkinis, E, Paraskevis, D, Magiorkinis, G, Chryssou, S, Chini, M, Lazanas, M, Paparizos, V, Saroglou, G, Antoniadou, A, Giamarellou, E, Karafoulidou, A, Hatzakis, A

“…The widespread use of antiviral drugs against HIV has increased the prevalence of HIV-1 resistant strains among naïve individuals due to transmission of…”
Get full text

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016 by Antinori, A, Bartmeyer, B, Beniowski, M, Bonnet, F, Brannstrom, J, Casabona, J, Castagna, A, Chene, G, Costagliola, D, Monforte, AD, Valero, JD, De Wit, S, Faetkenheuer, G, Furrer, H, Gasiorowski, J, Jadand, C, Kirk, O, Laut, KG, Lazanas, M, Suarez-Lozano, I, Lundgren, J, Mikhalik, J, Mocroft, A, Moreno, S, Mussini, C, Obel, N, Paduta, D, Raben, D, Reiss, P, Riordan, A, Sabin, C, Smidt, J, Torti, C, Trofimova, T, Vassilenko, A, Vasylyev, M, Warszwski, J, Wittkop, L, Yakovlev, A, Zangerle, R

“…Abstract Background Late presentation (LP), defined as a CD4 count < 350/mm 3 or an AIDS-event at HIV-diagnosis, remains a significant problem across Europe…”
Get full text

HIV continuum of care: bridging cross-sectional and longitudinal analyses by Touloumi, Giota, Thomadakis, Christos, Pantazis, Nikos, Papastamopoulos, Vasileios, Paparizos, Vasilios, Metallidis, Simeon, Adamis, Georgios, Chini, Maria, Psichogiou, Mina, Chrysos, Georgios, Sambatakou, Helen, Barbunakis, Emmanouil, Vourli, Georgia, Antoniadou, Anastasia

“…The aim of this study was to propose a unified continuum-of-care (CoC) analysis combining cross-sectional and longitudinal elements, incorporating time spent…”
Get full text

Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece by Touloumi, Giota, Kalpourtzi, Natasa, Papastamopoulos, Vasileios, Paparizos, Vasilios, Adamis, Georgios, Antoniadou, Anastasia, Chini, Maria, Karakosta, Argiro, Makrilakis, Konstantinos, Gavana, Magda, Vantarakis, Apostolos, Psichogiou, Mina, Metallidis, Simeon, Sipsas, Nikolaos V, Sambatakou, Helen, Hadjichristodoulou, Christos, Voulgari, Paraskevi V, Chrysos, George, Gogos, Charalambos, Chlouverakis, Grigoris, Tripsianis, Grigoris, Alamanos, Yannis, Stergiou, George

“…Although combined antiretroviral therapy has substantially improved the prognosis of people living with HIV (PLHIV), mortality remains higher compared to the…”
Get full text

Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy by Pantazis, Nikos, Papastamopoulos, Vasilios, Paparizos, Vasilios, Metallidis, Simeon, Adamis, Georgios, Antoniadou, Anastasia, Psichogiou, Mina, Chini, Maria, Sambatakou, Helen, Sipsas, Nikolaos V, Gogos, Charalambos, Chrysos, Georgios, Panagopoulos, Periklis, Katsarou, Olga, Gikas, Achilleas, Touloumi, Giota

“…OBJECTIVE:Combined antiretroviral treatment (cART) results in profound immunologic improvement, but it is unclear whether CD4 cell counts return to levels…”
Get full text

Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds by Lazanas, M C, Tsekes, G A, Papandreou, S, Harhalakis, N, Scandali, A, Nikiforakis, E, Saroglou, G

Get more information